ADC Therapeutics (NYSE:ADCT) said it has completed enrollment in the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Vistagen (NASDAQ:VTGN) announced topline results from the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder.
Stoke Therapeutics Inc. (NASDAQ:STOK) said it has completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen, an investigational RNA medicine for Dravet syndrome.
Air Products (NYSE:APD) announced it will not proceed with the Louisiana Clean Energy Complex, citing expected financial returns not meeting the company’s strict criteria.
FAST TRACK GROUP (NASDAQ:FTRK) reported audited financial results for the fiscal year ended February 28, 2026, showing total revenue of $1.7 million, a 112% increase from the prior year.
Flash Sports & Media Holdings (NASDAQ:FLZH) signed a confidential, non-binding letter of intent to acquire a 51% controlling interest in Dubai-based hospitality group Nooa.
The U.S. Food and Drug Administration selected seven companies for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities.
PowerBank (NASDAQ:PBK) announced that its subsidiary, Abundant Solar Power, has signed an operations and maintenance agreement with Honeywell for a 21 MW portfolio of three New York community solar projects.
Unicycive Therapeutics (NASDAQ:UNCY) said the U.S. Food and Drug Administration issued a Complete Response Letter for its resubmitted new drug application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis.
Patrick Industries (NASDAQ:PATK) and LCI Industries (NYSE:LCII) have entered into a definitive agreement to combine in an all-stock merger.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
